Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Seviprotimut-L stimulates humoral and cellular immune response, is in clinical development as a potential adjuvant treatment for patients 60 years and younger with Stage IIB or IIC melanoma.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 11, 2022
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Details : U.S. Food and Drug Administration (FDA) has granted Polynoma's application for Fast Track designation of seviprotimut-L, its melanoma cancer vaccine for the adjuvant treatment of stage IIB/IIC melanoma patients post-resection to improve recurrence-free s...
Brand Name : POL-103A
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 23, 2020
Details : Study data show a durable recurrence-free survival clinical benefit in patients with localized melanoma, supporting the potential use of seviprotimut-L as an adjuvant treatment.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 13, 2020
LOOKING FOR A SUPPLIER?